Business and financial data analysis covering audit, strategy, accounting, marketing, investment, and profit reporting.

Decoding CMS drug pricing models, benchmarks and MFN alignment

Authors

5 minute read 23 Apr 2026

Explainer of CMS Medicare and Medicaid drug pricing models and their interaction with Most Favored Nation deals.

In brief
  • CMS is using demonstration authority to test CMS drug pricing reforms, including Medicare drug pricing approaches that reference global markets.
  • New rebate structures and participation rules may reshape pharma regulatory compliance, pharmaceutical manufacturing compliance and pricing strategy.
  • Key questions remain about CMS Innovation Center drug pricing models, alignment with federal pricing programs, and durability of voluntary pricing agreements.

Understanding the CMS drug pricing demonstrations

The CMS Innovation Center is testing new ways to lower US drug costs in Medicare and Medicaid by tying payments more closely to prices paid in other higher-income countries. These efforts expand the federal government’s use of international reference pricing and rely on the Innovation Center’s existing authority to test new payment models. At the center of this strategy are two proposed mandatory Medicare demonstrations:

  • The Global Benchmark for Efficient Drug Pricing or GLOBE Model, which applies to Part B drugs (typically physician-administered drugs)
  • The Guarding U.S. Medicare Against Rising Drug Costs or GUARD Model, which applies to Part D drugs (retail prescription drugs)

How EY can help

Both models would use international price benchmarks to set manufacturer rebate obligations, run for roughly five years and apply in selected geographic areas. The Administration also has proposed two voluntary drug pricing models:

  • GENErating cost Reductions fOr U.S. Medicaid or GENEROUS Model, a voluntary pilot under which participating manufacturers would offer supplemental rebates tied to international pricing benchmarks.
  • Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth or BALANCE Model, which aims to pair lower GLP-1 prices with lifestyle and nutrition interventions across Medicaid and Medicare Part D.

How CMS drug pricing models fit together with MFN commitments

The Innovation Center announced the new drug pricing demonstrations alongside a growing set of voluntary “Most Favored Nation” (MFN) agreements between the Administration and drug manufacturers. These agreements generally reflect manufacturer commitments to align certain US prices with international benchmarks, including offering MFN‑based pricing in Medicaid, launching select new products at MFN prices and providing discounted direct‑to‑consumer access for certain drugs, among other concessions. Due to their voluntary nature, the Administration is using the Innovation Center as a vehicle to help carry out certain elements of these MFN‑related commitments:

Looking forward: key questions on CMS drug pricing implementation and impact

  • How will CMS coordinate overlap between confidential MFN agreements and Medicaid and Medicare demonstrations?
  • How will CMS monitor and enforce MFN pricing commitments and model exemptions under confidential, voluntary White House agreements?
  • What pricing rules apply when MFN agreements expire — especially if participation ends before related demonstrations conclude?
  • What will be the level of interest and uptake in voluntary models by states, manufacturers and plans?
  • How will the Medicaid and Medicare demonstrations interact with the maximum fair price negotiated under the Medicare Drug Price Negotiation Program?
  • Will participation in these models translate into meaningful drug cost savings for patients and taxpayers?

Overview of CMMI drug pricing models


Summary 

CMS is experimenting with new drug pricing approaches that blend required participation with opt‑in arrangements across federal health programs. By drawing on global price benchmarks and alternative CMS drug pricing models, the initiatives raise important questions for Medicare drug pricing policy and pharma regulatory compliance. Attention now turns to practical execution, interaction with existing pricing frameworks, and whether these efforts can achieve lasting cost containment without disrupting market incentives.


About this article

Authors

Related topics
Health
Life Sciences

How EY can help

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.